Please login to the form below

Not currently logged in
Email:
Password:

Ann Barbier joins Translate Bio as its chief medical officer

She will take responsibility for leading the US biotech's clinical R&D

Ann BarbierUS-based biotech Translate Bio has appointed Ann Barbier as its new chief medical officer.

She brings 20 years' of drug discovery and development experience to her new role, which will see her take responsibility for leading all clinical research and development, medical affairs and related functions at Translate Bio.

She said: “With near-term clinical programmes in cystic fibrosis and OTC deficiency, Translate Bio is approaching a critical and exciting time.

“Our platform has the potential to be transformative for patients, and I am incredibly excited about the opportunity to join an experienced management team dedicated to finding innovative treatments in areas of high unmet need.”

Prior to joining Translate Bio, Barbier was vice president of clinical development, rare genetic diseases at Agios Pharmaceuticals, where she led the development programme of a small molecule in rare benign haematological diseases.

She has also served Shire in various roles including global clinical development lead and senior medical director, and her career experience has seen her work at Envivo, Johnson & Johnson and Aventis.

15th November 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....